The intracellular localization of Cu,Zn superoxide dismutase (superoxide:superoxide oxidoreductase, EC 1.15.1
Superoxide dismutases (SODs; superoxide:superoxide oxidoreductase, EC 1.15.1.1) are a family of enzymes unusual in that their substrate is an unstable and toxic free radical produced as a by-product of oxidative metabolism. These enzymes protect cells by catalyzing the dismutation of the superoxide radical to 02 and H202 (1) . In mammalian cells, three forms of SOD-Mn SOD, Cu,Zn SOD, and extracellular Cu,Zn SOD-have been identified. They are encoded by three separate genes and differ in their amino acid sequences and their localization (2) (3) (4) . The human Cu,Zn SOD is a dimer of identical subunits, each consisting of 153 amino acids and containing one Cu and one Zn ion. Although usually described as a cytoplasmic enzyme, the subcellular localization of Cu,Zn SOD has been ascribed to various organelles. This view is based in part on cell fractionation experiments, in which the enzyme activity was found predominantly in the cytosol but also in the fraction corresponding to the mitochondrial intermembrane space (5) or with the lysosomal fraction (6) . More recent investigations involving immunolocalization of the enzyme with a polyclonal antibody have reported the presence of Cu,Zn SOD in the cytoplasmic matrix, the nucleus, and the lysosomes of rat liver hepatocytes (7) .
We suspected that Cu,Zn SOD might be a peroxisomal enzyme for the following reasons: (i) xanthine oxidase, which has recently been shown to be localized within peroxisomes (8, 9) , generates toxic superoxide radicals as a reaction by-product, (ii) H202, a toxic product of superoxide dismutation, is removed by catalase, which is uniquely located in peroxisomes in mammals, (iii) catalase may require protection from superoxide radicals, which have been shown to inactivate it (10) , and (iv) Cu,Zn SOD contains a tripeptide Ser-Arg-Leu close to the C terminus that might act as a peroxisomal targeting signal. We have therefore reexamined the cellular localization of the enzyme both in mammalian cells and in yeast expressing the human cDNA.
MATERIAL AND METHODS
Monoclonal Antibodies. BALB/c mice were immunized with a Cu,Zn SOD/p31 fusion protein produced and purified from Escherichia coli (11) . Spleen cells were fused with the mouse myeloma cell line P3x63 Ag.653 (12) and cells were plated in microtiter plates. Wells with cell growth were screened for SOD-specific antibodies by ELISA. The four monoclonal antibodies used in this study react with both native and denatured human Cu,Zn SOD and are designated CZSODF2, CZSODA3, CZSODA6, and CZSODA7. Antibody was purified from ascites fluid by ammonium sulfate precipitation followed by DEAE-Sepharose chromatography (13) .
Yeast Strains and Culture Conditions. Saccharomyces cerevisiae strain P017 [Mata Leu2 (cii°)] (14) was transformed with plasmid pC1/1 PGAPHSODC6A,C111S (15) encoding expression of a thermostable human Cu,Zn SOD that has normal structure and activity (16) . The pC1/1 PGAPHSODC6A, CillS shuttle vector contains the 2-,um yeast plasmid, pBR322, the defective yeast Leu2 gene, and the human Cu,Zn SOD cDNA under the transcriptional control of the promoter for the yeast glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (15) . Colonies were selected on plates lacking leucine, inoculated into 5-ml cultures of minimal dextrose medium lacking leucine, and grown to stationary phase at 30'C with aeration (17) . Cultures (2 ml) were pelleted by centrifugation, washed once with oleic acid medium, and resuspended in 25 ml of oleic acid medium and grown 24 hr at 30'C with aeration. Sterile filtered oleic acid medium contained the following: yeast nitrogen base (6.7 g/liter) (Difco), yeast extract (0.5 g/liter) (Difco), oleic acid (1 ml/liter) (Sigma), Tween 80 (0.5 ml/liter) (Sigma), and 1 M CUSO4 (100 ml/liter) (Cu,Zn SOD-producing strains).
Immunofluorescence Microscopy. Indirect immunofluorescence of Hep-G2 cells and fibroblasts from normal and Zellweger patients (obtained from D. Applegarth, British Columbia Children's Hospital) was performed as described (18) . Primary monoclonal antibodies to human Cu,Zn SOD and rabbit antibodies to human catalase were used at 50 and 10 ,ug/ml, respectively. A monoclonal antibody to human Mn SOD (19) , instead of the monoclonal antibodies to Cu,Zn SOD, was used as a control antibody. The secondary antibodies were rhodamine-conjugated goat anti-rabbit IgG and fluoresceinconjugated goat anti-mouse IgG. Cells were photographed in the same plane of focus with a Leitz Aristoplan microscope using the appropriate filters for rhodamine and fluorescein.
Immunocryoelectron Microscopy. Cryoultramicrotomy, immunolabeling of cryosections, and thin plastic embedding of yeast cells were performed as described (20) . The characterization of the rabbit antibody against the peroxisome targeting signal has been described elsewhere (21) . The immunolabeled sections were observed without poststaining in a Philips CM12 transmission electron microscope equipped with a 10-,m-diameter objective aperture.
Abbreviation: SOD, superoxide dismutase.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (21, 26) . L, lipid droplet; P, peroxisomes. (Bars = 0.1 /im.) SOD and a rabbit anti-human catalase antibody were carried out on Hep-G2 cells. At low magnification, the immunolabeling pattern for Cu,Zn SOD ( Fig. 2A) is indistinguishable from that for catalase (Fig. 2B) . Careful examination of the immunofluorescence patterns at higher magnification reveals that the vesicular structures labeled by the anti-Cu,Zn SOD and anti-catalase antibodies are superimposable (Fig. 2 C and D) . Since catalase is a classical peroxisomal marker, these results indicate that Cu,Zn SOD is predominantly concentrated within the peroxisomes in human hepatoma cells. In addition, a monoclonal antibody against human Mn SOD (19) was substituted in the same immunolabeling protocol. The anti-Mn SOD monoclonal antibody gave the typical vermiculate immunolabeling pattern of the mitochondrial compartment (Fig.  2E) , which is totally different from the punctate pattern characteristic of peroxisome labeling (Fig. 2F) . This shows that the peroxisomal localization of Cu,Zn SOD was not due to cross-reactivity of the secondary antibody (the fluoresceinlabeled goat anti-mouse IgG) with a peroxisomal protein. All four anti-human Cu,Zn SOD monoclonal antibodies labeled the peroxisomes in single immunolabeling experiments (data not shown).
Human Cu,Zn SOD Is Targeted to the Peroxisomes of the Yeast S. cerevisiae. To ensure that the results obtained with Hep-G2 cells were not due to cross-reactivity of the antiCu,Zn SOD monoclonal antibodies with an epitope(s) present on a peroxisomal protein unrelated to Cu,Zn SOD, we used transformed yeast cells expressing the human enzyme (15) . Expression of the human enzyme in transformed, but not in control, cells was confirmed by Western blot analysis (Fig. 1,  lanes 6 and 7) . The antibodies to the human protein did not recognize yeast Cu,Zn SOD (lanes 3 and 5). S. cerevisiae contains few visible peroxisomes when grown under normal conditions (24) , but peroxisomes multiply upon growth on oleic acid (25) . Immunocryoelectron microscopy of yeast cells grown in oleic acid medium showed that the human enzyme was concentrated in the matrix of small subcellular organelles surrounded by a single membrane (Fig. 3A) . Morphologically similar organelles were detected in the cytoplasm of wild-type cells but, as expected, they were not labeled with the antihuman Cu,Zn SOD antibody (Fig. 3B) . Immunolabeling with antibodies to the peroxisomal targeting signal confirmed that the organelles containing the human enzyme were indeed peroxisomes (Fig. 3C) . These antibodies recognize multiple peroxisomal proteins in mammalian cells and eukaryotic microorganisms including S. cerevisiae (21, 26) .
Cu,Zn SOD Is Cytoplasmic in the Fibroblasts of Zellweger Syndrome Patients. Zellweger syndrome is due to an autosomal recessive mutation that causes incomplete assembly of peroxisomes (27) . Although the peroxisomal membranes are Cell Biology: Keller et (28), most of the peroxisomal enzymes that are normally transported within the organelles remain in the cytosol. It was therefore of interest to determine whether Cu,Zn SOD was mislocated along with other peroxisomal matrix proteins. Fibroblasts of normal (Fig. 4 A  and B ) and Zellweger patients (Fig. 4 C and D) labeled for Cu,Zn SOD (Fig. 4 A and C) and catalase (Fig. 4 B and D) are shown in Fig. 4 . The immunolabeling shows that Cu,Zn SOD is also a peroxisomal enzyme in normal human fibroblasts. In contrast, both enzymes were localized throughout the cytoplasm in Zellweger fibroblasts.
DISCUSSION
We have demonstrated the peroxisomal localization ofCu,Zn SOD by showing that the enzyme (i) colocalized with catalase in the peroxisomes of Hep-G2 cells and normal fibroblasts, (it) is targeted to peroxisomes in S. cerevisiae transformants expressing human Cu,Zn SOD but is not present in control cells, and (ifi) is localized with catalase in the cytoplasm of fibroblasts from Zellweger patients.
Cu,Zn SOD is widely described as a cytoplasmic enzyme, although the published literature regarding the subcellular localization of the enzyme in mammalian cells is somewhat contradictory. Geller and Winge (6) presented data indicating that the enzyme cosegregated with lysosomal enzymes in cell fractionation experiments. Indeed, our own experiments using conventional cell fractionation showed that the majority of the enzyme activity was associated with the fraction containing the lysosomes (data not shown). It is well documented that portions of several peroxisomal matrix proteins are routinely found in other cell fractions, even when using the most moderate methods of cell disruption (29) . We suspect that Cu,Zn SOD is released from peroxisomes under the conditions used for isolation and purification of the organelles. More recently, using an immunoelectron microscopy approach, Chang et al. (7) found Cu,Zn SOD in virtually all subcellular compartments of rat hepatocytes, with the exception of the endoplasmic reticulum and the Golgi apparatus. Although the Iysosomes contained the highest concentration, most of the enzyme was located in the cytoplasmic and nuclear matrices. One important difference between these studies and our own is that we have used monoclonal antibodies raised against a recombinant protein rather than a polyclonal antibody raised against the protein purified from tissue. Unlike polyclonal antibodies, monoclonal antibodies cannot contain antibodies against proteins contaminating the immunizing antigen preparation. The (30) . Usually situated at the extreme C terminus of several peroxisomal proteins, the tripeptide can be identified at internal locations in others. The C-terminal portion of human catalase that can act as a peroxisomal targeting signal contains the tripeptide Ser-HisLeu 10 amino acids from the C terminus (31) . Therefore, we plan to determine whether the enzyme is sorted to the peroxisomes by the tripeptide Ser-Arg-Leu at amino acid positions 142-144, 9 residues before the C terminus, or by another as yet unidentified signal. The targeting and transport of the human enzyme into the peroxisomes of S. cerevisiae transformants is consistent with recent findings showing that the sorting of peroxisomal proteins has been conserved throughout eukaryotic evolution (21, 26) .
What are the biological implications of a peroxisomal localization for Cu,Zn SOD? First, an important function of peroxisomes appears to be antioxidant defense by removal of H202 and superoxide. By analogy, the mitochondrion, which also generates superoxide radicals, contains Mn SOD. Thus, it seems evident that compartmentalization of these processes results in containment of potentially damaging forms of oxygen. Second, Mn SOD and Cu,Zn SOD are the only two intracellular SODs, which suggests that the majority of the SOD activity resides in the mitochondria and the peroxisomes. We therefore suspect that in addition to electron transfer proteins in mitochondria (31) and xanthine oxidase in peroxisomes (8, 9) , other enzymes that produce superoxide will be identified in these organelles. Conversely, it should be advantageous to confine proteins that are rapidly inactivated by superoxide (23, 32) to the cytoplasm. Both immunofluorescence and immunocryoelectron microscopy indicate that a fraction of Cu,Zn SOD is present in the cytoplasm (Fig. 2E and Fig. 4 A and C) . Therefore, it seems probable that there is also some SOD activity in the cytoplasm due to SODs in transit to the mitochondria or peroxisomes (see Fig. 3A ).
